Printer Friendly

JOHN HANCOCK LAUNCHES GLOBAL Rx FUND

 JOHN HANCOCK LAUNCHES GLOBAL Rx FUND
 BOSTON, Jan. 21 /PRNewswire/ -- John Hancock Mutual Funds announced


today the introduction of a mutual fund that invests globally in health- care, pharmaceutical and biotechnology stocks.
 John Hancock Global Rx Fund is being introduced during a time when health and biotechnology funds have been outpacing other types of funds. Health-care funds were the top performers for the one-, five-, and 10-year periods ending Dec. 31, 1991, according to Lipper Analytical Services.
 Despite the relative outperformance of this sector, fund manager Paul Secord believes the long-term prognosis for the health-care industry is robust. "Increased spending for medical services, an aging world population and a growing demand for long-term care are converging, inescapable moving forces," said Secord, who also manages John Hancock Growth Fund. In 1990, more than $662 billion was spent on health and medical services in the United States alone, Secord noted, adding that the figure--which was nearly one-eighth of the nation's GNP--could double over the next several years.
 Health-care stocks have also shown an ability to withstand fluctuations in market cycles, Secord said. "Americans will continue to have a need for health care regardless of the economic environment," he said.
 In an unusual twist for a mutual fund, John Hancock is assembling a unique scientific advisory board which will provide technical advice to the fund. Experts in health, medicine, research and biotechnology, will work with portfolio management to review new scientific developments and evaluate potential emerging industry leaders.
 Another important feature of John Hancock Global Rx Fund is its ability to invest in private placements, Secord said. "Some of the most promising investment opportunities come from emerging companies that are not yet recognized by the marketplace," Secord said. "This is another area where the scientific advisory board will add value."
 The fund is part of John Hancock's line-up of sector funds which includes John Hancock Global Technology Fund, World Fund-Pacific Basin Equities Portfolio, and National Aviation & Technology Fund. The minimum initial investment for John Hancock Global Rx Fund is $1,000, $500 for retirement accounts or $25 through an automatic investment program.
 John Hancock Mutual Funds manages more than $3 billion and is affiliated with John Hancock Mutual Life Insurance Company, one of the nation's most respected financial services firms.
 -0- 1/21/92
 /CONTACT: Bill Benintende of John Hancock Mutual Funds, 617-375-1883/ CO: John Hancock Mutual Funds ST: Massachusetts IN: FIN SU: PDT


DD-SD -- NE006 -- 1735 01/21/92 10:49 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 21, 1992
Words:410
Previous Article:THE GNI GROUP REPORTS BEST EVER SECOND QUARTER RESULTS
Next Article:SPECTRANETICS ANNOUNCES INITIAL PUBLIC OFFERING OF COMMON STOCK
Topics:


Related Articles
John Hancock Funds Adds Nicholas-Applegate to Fund Lineup; San Diego Manager to Subadvise Hancock's International and Global Mutual Funds.
John Hancock Funds tTo Acquire U.S. Global Leaders Growth Fund.
John Hancock Funds Completes Acquisition of U.S. Global Leaders Growth Fund; Acquisition is Vital Part of Fund Family's Strategy to Grow Assets.
John Hancock Patriot Global Dividend Fund Declares Monthly Dividend.
John Hancock Advisers Releases Portfolio Information for Closed-End Funds.
John Hancock Patriot Global Dividend Fund Declares Monthly Dividend.
John Hancock Advisers Releases Portfolio Information for Closed-End Funds.
John Hancock Patriot Global Dividend Fund Declares Monthly Dividend.
John Hancock Patriot Global Dividend Fund Declares Monthly Dividend.
John Hancock Advisers Releases Portfolio Information for Closed-End Funds.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters